membrane α-helix B, the largest α-helix predicted to lie at the interface between the ClC-2 channel and the membrane. Our results showed that, in contrast to the claims in the retracted paper, these altered proteins did not reach the plasma membrane and did not exert any dominant negative effect on the function of normal ClC-2 (ref. 3) . Also, in regard to the 2776_2788del11 mutation, using a minigene approach, we could find no difference in the proportion of exon-skipped to normally spliced mRNA as a consequence of the mutation and, on this basis, predicted no alteration in ClC-2-channel expression in affected individuals. A third mutation, G8794A, produces an amino acid replacement (G715E) purportedly associated with a gain of function 1 , allowing the channel to be conductive at reduced intracellular Cl -concentration. We could not reproduce this result of the retracted paper either 3 . The contrast between our results and those in the retracted paper was reflected in the first paragraph of our Discussion section, which reads: "Our results are in marked contrast to those reported previously by Haug et al. and suggest that the pathophysiological mechanisms proposed by these authors to account for the phenotype need to be revised" 3 .
The other paper cited as supporting the functional results of the retracted paper is that by Blanz et al. 4 , in which we in fact confirm the failure to reproduce the dominant negative effect of mutation 3792_3793insG (M200fsX231) reported by Haug et al. 1 . We concluded that "our electrophysiological analysis of CLCN2 sequence abnormalities described in patients with epilepsy (Haug et al.) did not provide evidence for them being epileptogenic" 4 . In the same paper 4 , we showed that other CLCN2 sequence variants identified more recently in patients with epilepsy 5 did not alter the biophysical properties of ClC-2 and were also found in humans not displaying epilepsy. We have also reported that the ClC-2-null genotype in mice failed to induce spontaneous seizures or to alter the seizure threshold for the response of the animals to proconvulsants 4, 6 . We discussed these points in recent reviews 7, 8 and had concluded before the retraction of the paper by Haug et al. 1 that "the sum of these observations… warrants skepticism toward the proposed causative role of ClC-2 in epilepsy" 7 .
These observations both suggest that even the functional results of the retracted paper cannot be relied upon, and they also support the view that there is no basis to claim that CLCN2 plays a role in epilepsy. 
